Pro-tumorigenic paracrine action of the PPARγ agonist rosiglitazone (RGZ) in melanoma has been reported, however7,8, showing that PPARγ activation results in complex and context-dependent outcomes, the molecular bases of which remain poorly characterized. The gene discussed is PPARG; the disease is melanoma.